Baricitinib

• Background:

  Baricitinib acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2, therby reducing cytokine release and suppressing the innate and adaptive immune systems. It was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (“cytokine storm”) induced by SARS-CoV-2 infection.

• Description:

  Kinase inhibitor

• Product Name Alternative:

  1- (Ethylsulfonyl) -3-[4- (7H-pyrrolo[2,3-d]pyrimidin-4-yl) -1H-pyrazol-1-yl]-3-azetidineacetonitrile, INCB028050, LY3009105

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cell Signaling | Growth Factors | TNF

• Purity:

  >98% (HPLC) ; NMR (Conforms)

• Weight:

  0.005

• Format:

  White to off-white powder

• Solubility:

  May be dissolved in DMSO (30 mg/ml); or DMF (50 mg/ml)

• Molecular Formula:

  C16H17N7O2S

• Molecular Weight:

  371.4

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1."Summary of opinion for Olumiant" (PDF). European Medicines Agency (EMA). 15 December 2016. 2. Cantini F., et al. (2020) J. Infect. DOI: 10.1016/j.jinf.2020.04.017

• CAS Number:

  1187594-09-7